Department of Nutrition, University of North Carolina at Greensboro, Greensboro, NC 27412, USA.
Bone. 2010 May;46(5):1408-15. doi: 10.1016/j.bone.2010.01.376. Epub 2010 Jan 25.
There are few studies describing the extent to which low iron status affects osteoblastogenesis, despite evidence that iron deficiency produces adverse effects on bone density. The purpose of this study was to evaluate alterations in intracellular iron status by measuring iron-regulated gene and protein expression and to describe development of osteoblast phenotype in primary cells treated with iron chelator deferoxamine (DFOM) during differentiation. Using the well-described fetal rat calvaria model, cells were incubated with 0-8 microM DFOM throughout differentiation (confluence to day (D) 21), or only during early differentiation (confluence to D13-15) or late differentiation (D13-15 to D21). Changes in intracellular iron status were determined by measuring alterations in gene and protein expression of transferrin receptor and ferritin light chain and heavy chain. Development of osteoblast phenotype was monitored by measuring expression of genes that are known to be up-regulated during differentiation, analyzing the percentage of mineralized surface area, and counting the number of multi-layered bone nodules at the end of culture. Results indicate that treatment throughout differentiation with 8 microM DFOM alters iron-regulated genes and proteins by mid-differentiation (D13-15) in a pattern consistent with iron deficiency with concomitant down-regulation of osteoblast phenotype genes, especially osteocalcin. Additionally, alkaline phosphatase staining was lower and there was about 70% less mineralized surface area (p<0.05) by D21 in wells treated throughout differentiation with 8 microM DFOM compared to control. Down-regulation of osteocalcin and alkaline phosphatase mRNA (p<0.05) and suppressed mineralization (p<0.05) was also evident at D21 in cells treated only during early differentiation. In contrast, treatment during late differentiation did not alter osteoblastic outcomes by D21. In conclusion, it appears that iron is required for normal osteoblast phenotype development, and that early rather than late differentiation events may be more sensitive to iron availability.
尽管有证据表明缺铁会对骨密度产生不利影响,但描述铁缺乏状态对成骨细胞生成影响的研究甚少。本研究旨在通过测量铁调节基因和蛋白表达来评估细胞内铁状态的变化,并描述在分化过程中用铁螯合剂去铁胺(DFOM)处理原代细胞时成骨细胞表型的发育。使用已充分描述的胎鼠颅骨模型,将细胞在 0-8 μM DFOM 中孵育,贯穿分化过程(汇合至第 21 天),或仅在早期分化(汇合至第 13-15 天)或晚期分化(第 13-15 天至第 21 天)时进行。通过测量转铁蛋白受体和铁蛋白轻链和重链的基因和蛋白表达的变化来确定细胞内铁状态的变化。通过测量已知在分化过程中上调的基因的表达、分析矿化表面积的百分比以及在培养结束时计数多层骨结节的数量来监测成骨细胞表型的发育。结果表明,在分化过程中用 8 μM DFOM 处理贯穿整个分化过程会在中期(第 13-15 天)改变铁调节基因和蛋白,其模式与铁缺乏一致,同时下调成骨细胞表型基因,尤其是骨钙素。此外,与对照相比,在整个分化过程中用 8 μM DFOM 处理的孔中,碱性磷酸酶染色较低,第 21 天时矿化表面积减少约 70%(p<0.05)。在仅早期分化时用药物处理的细胞中,骨钙素和碱性磷酸酶 mRNA 的下调(p<0.05)和矿化抑制(p<0.05)也在第 21 天明显。相比之下,在晚期分化时用药物处理不会在第 21 天改变成骨细胞的结果。总之,铁似乎是正常成骨细胞表型发育所必需的,并且早期分化事件而不是晚期分化事件可能对铁的可利用性更为敏感。